Ironwood Pharmaceuticals, Inc. - Class A Common Stock (NQ:IRWD)

4.030 +0.260 (+6.90%)

Delayed Quote Updated: 4:00 PM EST, Nov 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Ironwood Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 Next >

Ironwood Pharmaceuticals Raises Full-Year 2026 Financial Guidance Driven by Continued LINZESS U.S. Net Sales Growth and Strong Third Quarter Financial Performance

Today 7:05 EST

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Host Third Quarter 2026 Investor Update Call

October 28, 2026

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer

October 16, 2026

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference

September 03, 2026

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results

August 06, 2026

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call

July 30, 2026

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients

July 14, 2026

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

May 28, 2026

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)

May 27, 2026

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance

May 07, 2026

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)

May 04, 2026

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call

April 30, 2026

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026

April 23, 2026

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

March 04, 2026

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook

February 25, 2026

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call

February 18, 2026

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance

January 02, 2026

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance

November 10, 2025

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance

August 07, 2025

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Reports First Quarter 2025 Results

May 07, 2025

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

April 30, 2025

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance

April 25, 2025

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support

April 22, 2025

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide

April 14, 2025

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing

March 27, 2025

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance

February 27, 2025

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call

February 20, 2025

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future

January 29, 2025

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference

November 26, 2024

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference

November 13, 2024

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.